Seizures in glioma patients: An overview of incidence, etiology, and therapies.
cancer
epilepsy
glioma
review
seizure
Journal
Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403
Informations de publication
Date de publication:
15 Sep 2019
15 Sep 2019
Historique:
received:
10
05
2019
revised:
24
06
2019
accepted:
18
07
2019
pubmed:
29
7
2019
medline:
9
9
2020
entrez:
29
7
2019
Statut:
ppublish
Résumé
Gliomas are fatal brain tumors, and even low-grade gliomas (LGGs) have an average survival of less than a decade. Seizures are a common presentation of gliomas, particularly LGGs, and substantially impact quality of life. Glioma-related seizures differ from other focal epilepsies in their pathogenesis and in the likelihood of refractory epilepsy. We review factors that predict seizure activity and response to treatment, optimal pharmacologic and surgical management of glioma-related epilepsy, and the benefit of using newer anti-seizure medications in patients with gliomas. As surgery is so often beneficial with seizure reduction, we discuss oncologic and epilepsy surgery perspectives. Treatment of gliomas has the potential to ameliorate seizures and increase rates of seizure freedom. Prospective, well-powered studies are needed to provide more definitive answers for practitioners taking care of glioma patients with seizures.
Identifiants
pubmed: 31352293
pii: S0022-510X(19)30329-6
doi: 10.1016/j.jns.2019.07.026
pii:
doi:
Substances chimiques
Anticonvulsants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
80-85Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.